Literature DB >> 10343153

The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture.

J Satoh1, K Kurohara, M Yukitake, Y Kuroda.   

Abstract

The 14-3-3 protein belongs to a family of 30-kD proteins originally identified by two-dimensional analysis of brain protein extracts. Recently, the detection of the 14-3-3 protein in the cerebrospinal fluid (CSF) is utilized as a highly reliable test for the premortem diagnosis of prion diseases such as Creutzfeldt-Jakob disease. For the initial step, to clarify the biological implication of the CSF 14-3-3 protein in these diseases, its expression was investigated in neural tissues and cultures and CSF samples from patients with a variety of neurological diseases by Western blot analysis and immunocytochemistry. The constitutive expression of the 14-3-3 protein was identified in all neural and nonneural tissues examined. It was expressed in all neurons, astrocytes, oligodendrocytes, and microglia in culture with its location in both cytoplasmic and nuclear regions. The 14-3-3 protein was detected in the CSF of 8 out of 71 patients, including 1 Gerstmann-Sträussler-Scheinker disease patient and 7 patients with prion-unrelated neurological diseases, such as meningoencephalitis of viral, bacterial, or tuberculous origin, multiple sclerosis, and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. These results suggest that the 14-3-3 protein expressed constitutively at substantial levels in both neurons and glial cells might be released into the CSF as a disease-nonspecific consequence of the extensive brain damage and indicate that the analysis of the 14-3-3 protein in the CSF is not useful as a screening test for prion diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10343153     DOI: 10.1159/000008054

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  15 in total

1.  Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease.

Authors:  Numthip Chitravas; Richard S Jung; Diane M Kofskey; Janis E Blevins; Pierluigi Gambetti; R John Leigh; Mark L Cohen
Journal:  Ann Neurol       Date:  2011-06-14       Impact factor: 10.422

2.  Detection of CSF 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease Patients Using a New Automated Capillary Western Assay.

Authors:  A Fourier; A Dorey; A Perret-Liaudet; I Quadrio
Journal:  Mol Neurobiol       Date:  2017-05-16       Impact factor: 5.590

3.  Differential diagnosis of Jakob-Creutzfeldt disease.

Authors:  Ross W Paterson; Charles C Torres-Chae; Amy L Kuo; Tim Ando; Elizabeth A Nguyen; Katherine Wong; Stephen J DeArmond; Aissa Haman; Paul Garcia; David Y Johnson; Bruce L Miller; Michael D Geschwind
Journal:  Arch Neurol       Date:  2012-12

Review 4.  Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease.

Authors:  Gianluigi Zanusso; Salvatore Monaco; Maurizio Pocchiari; Byron Caughey
Journal:  Nat Rev Neurol       Date:  2016-05-13       Impact factor: 42.937

5.  Insulin suppresses collagenase stimulatory effect of stratifin in dermal fibroblasts.

Authors:  Eugene Lam; Edward E Tredget; Yvonne Marcoux; Yunyuan Li; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

6.  The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes.

Authors:  Jun-Ichi Satoh; Takashi Yamamura; Kunimasa Arima
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 7.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

Review 8.  The role of stratifin in fibroblast-keratinocyte interaction.

Authors:  Abelardo Medina; Abdi Ghaffari; Ruhangiz T Kilani; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2007-07-24       Impact factor: 3.396

Review 9.  Clinical Use of Improved Diagnostic Testing for Detection of Prion Disease.

Authors:  Mark P Figgie; Brian S Appleby
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

10.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.